SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections